Emergent BioSolutions Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report6 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−29.58%
vs ±14.3% implied · ×2.07
shaded = implied · ▲▼ = realized
SentenceIn January 2025, the Company announced an agreement with Hikma Pharmaceuticals Inc. ("Hikma") in which the Company obtained exclusive commercial rights for product sales and marketing in the United States and Canada to Hikma's KLOXXADO ® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent.
EBS 10-Kaccession 0001367644-26-000015
SentenceThe Emergent Agreements contemplate that we will enter into one or more binding Master Manufacturing Services Agreements, whereby Emergent will provide contract development and manufacturing services to produce our fully-human polyclonal antibody products.
SentenceFor example, in July 2023, we were awarded a 10-year contract by BARDA for the advanced development, manufacturing scale-up, and procurement of Ebanga TM (ansuvimab-zykl) treatment for Ebola.
EBS 10-Kaccession 0001367644-26-000015
SentenceIn February 2025, Bavarian Nordic announced that the FDA approved CHIKV VLP under the Priority Review, which triggered a $30.0 million development milestone payment to the Company.
EBS 10-Kaccession 0001367644-26-000015
SentenceThe decrease was due to lower volumes of CYFENDUS ® sales to the USG and international customers, primarily due to the impact of timing, partially offset by increases in ANTHRASIL ® sales to the Canadian government and BioThrax ® sales to foreign governments.
EBS 10-Kaccession 0001367644-26-000015
SentenceIn addition, for the "Big Four" federal agencies—the DVA, the DoW, the PHS (including the Indian Health Service), and the Coast Guard—we must make covered drugs available at pricing that is capped at the statutory federal ceiling price ("FCP").
EBS 10-Kaccession 0001367644-26-000015
SentenceCompliance with reporting and other requirements of these federal programs is a pre-condition to: (i) the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii) procurement of our products by the Department of Veterans Affairs ("DVA"), and by covered entities under the 340B/PHS program.
EBS 10-Kaccession 0001367644-26-000015
SentenceOur current procurement contracts with the HHS and the DoW are generally fixed price contracts.
EBS 10-Kaccession 0001367644-26-000015
SentenceThe decrease was primarily attributable to the one time $50.0 million arbitration settlement with Janssen related to the 2022 termination of the Janssen Agreement (the "Settlement Agreement"), which was paid in 2024, coupled with lower revenue from the Company's Camden facility in the current year, which was sold to Bora in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.
EBS 10-Kaccession 0001367644-26-000015
SentenceIn addition, for the "Big Four" federal agencies—the DVA, the DoW, the PHS (including the Indian Health Service), and the Coast Guard—we must make covered drugs available at pricing that is capped at the statutory federal ceiling price ("FCP").
EBS 10-Kaccession 0001367644-26-000015
SentenceIn July 2024, the Company entered into the Stock and Asset Purchase Agreement (the "RSDL ® Agreement") with SERB Pharmaceuticals, through its wholly owned subsidiary BTG International Inc. (collectively, "SERB"), pursuant to which, among other things, the Company sold its worldwide rights to RSDL ® , to SERB (the "RSDL ® Transaction").
EBS 10-Kaccession 0001367644-26-000015
SentenceIf priorities for the Strategic National Stockpile ("SNS") change generally, or as a result of the conclusion of the USG's audit of the SNS, or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of CYFENDUS ® or BioThrax ® vaccines may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling CYFENDUS ® in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.
EBS 10-Kaccession 0001367644-26-000015
SentenceThe U.S. government ("USG") is the largest purchaser of our Government - MCM products and primarily purchases our products for the Strategic National Stockpile, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies.
EBS 10-Kaccession 0001367644-26-000015
Emergent BioSolutions has 2 disclosed suppliers and 12 disclosed customers in SEC filings.
Emergent BioSolutions Inc.
6.79
Linked news
Expected move
Inputsspot 6.81exp Nov 20ATM strike 7ATM straddle 1.40IV 106%